{'fraction_non_alphanumeric': 0.010648596321393998, 'fraction_numerical': 0.003872216844143272, 'mean_word_length': 5.544303797468355, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Treatment for erythropoietic protoporphyria

tinct clinicopathological entity. It remains to be seen if and how indolent CD8 lymphoid proliferation of acral sites is incorporated into the forthcoming update of the World Health Organization’s Classification of Tumours of the Haematopoietic and Lymphoid Tissue and, until such times as reproducible and reliable diagnostic criteria are fully established and agreed, such a diagnosis should carry a note of caution. Currently, it is justifiable to manage a patient with presumed indolent CD8 lymphoid proliferation of acral sites initially in a conservative fashion with locally directed therapy, but with the caveat that an indolent course cannot be entirely guaranteed and that more aggressive therapy may be required if there are signs of progression. If the diagnostic utility of CD68 staining in this context can be fully verified, it will be a welcome addition to the diagnostic armoury for pathologists, providing reassurance for an initial nonaggressive approach to management.